Navigation Links
Fuisz Pharma Announces Patented Communication of Analyte Information Between Microchip Containing Smart Tablet and a Body Fluid Analyzer
Date:2/7/2011

MIAMI, Feb. 7, 2011 /PRNewswire/ -- Based on U.S. Patent 7,824,612 ("Body Fluid Analyzer and System including Same and Method for Programming Same"), Fuisz Pharma today announced the use of their patented Technology to create a new class of microchip containing smart tablets that communicate with personal body fluid analyzers.

These tablets wirelessly inform a body fluid analyzer of acceptable analyte values for body fluids, set by the drug company so that the analyzer can provide alerts where the patient's results exceed a threshold value.

Joseph Matus Fuisz, CEO of Fuisz Pharma, states, "We are seeing extraordinarily exciting developments around the use of microchip enabled smart tablets that can wirelessly communicate pertinent information to receiving devices.   At the same time, we are seeing further growth in the capabilities of personal body fluid analyzers and a greater appreciation for their use in drug development and personalized medicine.   Thus, we see the use of our patent 7,824,612 to enable the value added connection of tablet smart chips together with personal analyzers to convey a broad spectrum of pertinent information.   This enhances the function of smart tablets and analyzers alike."

About Fuisz Pharma:

Fuisz Pharma (www.fuisz.com) is a private pharmaceutical technology company originated by the Fuiszes. The Fuiszes have made substantial contributions in drug delivery including orally dissolving tablets and novel particle coating systems at Fuisz Technologies; inventing and developing thin film drug delivery technologies at Kosmos Pharma and MonoSol Rx, as well as independently developing extruded sheet technology, and have extensive experience working with big and specialty pharma.


'/>"/>
SOURCE Fuisz Pharma
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
2. SCOLR Pharma, Inc. Reports Second Quarter 2008 Financial Results
3. Par Pharmaceutical Reports Second Quarter 2008 Results
4. ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results
5. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
6. Best Practice Database Supports Bio-Pharma Product Launch
7. ADVENTRX Pharmaceuticals to Report Second Quarter 2008 Results
8. Pharmasset to Present at the Canaccord Adams Global Growth Conference on Tuesday, August 12th
9. Huifeng Bio-Pharmaceutical (HFGB) Announces USD $1.1 Million Supply Agreement with DNP International Co. Inc.
10. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
11. Lord Lewis Moonie to Serve as Special UK Government Advisor to PharmAthene
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/17/2017)... ... August 17, 2017 , ... ... market news outlet had provided a research update on Aytu Bioscience and cited ... product. , According to Soulstring, prescription rates for Natesto® have more than doubled ...
(Date:8/16/2017)... ... 16, 2017 , ... Tunnell Consulting announced today that four of ... Annual Meeting and Expo , to be held October 29 through November 1 in ... innovation to advance patient therapies.” , The ISPE Annual Meeting and Expo will feature ...
(Date:8/16/2017)... ... August 16, 2017 , ... ... a different cell type. Many treatments for specific cancers, such as breast, prostate, ... targeted treatment is androgen deprivation therapy for advanced prostate cancer. , This ...
(Date:8/16/2017)... (PRWEB) , ... August 16, 2017 , ... ... beneficial microbe delivery system, announced it has secured $2M in funding from an ... City Angels, Carmen Innovations, and SVG Thrive Fund. With this investment, 3Bar is ...
Breaking Biology Technology:
(Date:4/3/2017)... , April 3, 2017  Data ... precision engineering platform, detected a statistically significant ... product prior to treatment and objective response ... the potential to predict whether cancer patients ... to treatment, as well as to improve ...
(Date:3/30/2017)... YORK , March 30, 2017 Trends, ... type (physiological and behavioral), by technology (fingerprint, AFIS, iris ... voice recognition, and others), by end use industry (government ... and immigration, financial and banking, and others), and by ... Europe , Asia Pacific , ...
(Date:3/27/2017)... 27, 2017  Catholic Health Services (CHS) has ... Society (HIMSS) Analytics for achieving Stage 6 on ... . In addition, CHS previously earned a place ... an electronic medical record (EMR). "HIMSS ... of EMR usage in an outpatient setting.  This ...
Breaking Biology News(10 mins):